A federal appeals court will hear pharmaceutical maker Impax Laboratories LLC’s bid to overturn a 2019 antitrust order imposed by the Federal Trade Commission.
The U.S. Court of Appeals for the Fifth Circuit scheduled April 27 arguments in a case brought by the FTC that accuses Impax of illegally blocking access to a generic extended release pain reliever.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
